Suzanne Hendrix

5.4k citations

132 papers · 2.2k indexed · 2 hit papers · h-index 25

Impact in

Psychiatry and Mental health top 1%
- Dementia and Cognitive Impairment Research
Biological Psychiatry top 5%
- Tryptophan and brain disorders

Papers in ⓘ

Psychiatry and Mental health 42
- Dementia and Cognitive Impairment Research 41
Geriatrics and Gerontology 10
- Frailty in Older Adults 8

Co-authors: Kenton H. Zavitz (9 shared papers)Edward A. Swabb (7 shared papers)Mark Laughlin (6 shared papers)Gordon Wilcock (5 shared papers)Sandra E. Black (4 shared papers)Jeffrey L. Cummings (11 shared papers)Gene J. Ahlborn (1 shared paper)Oscar A. Pike (1 shared paper)
Journals: Alzheimer s & Dementia (50 papers)The Journal of Prevention of Alzheimer s Disease (15 papers)Neurology (12 papers)Alzheimer s Research & Therapy (7 papers)Alzheimer s & Dementia Translational Research & Clinical Interventions (6 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Suzanne Hendrix

120 papers receiving 2.2k citations

Hit Papers

align trajectories log scale

Donanemab: Appropriate use recommendations 2025 · 39 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 The Journal of Prevention of Alzheimer s Disease
2022 The Journal of Prevention of Alzheimer s Disease

Peers

Countries citing papers authored by Suzanne Hendrix

Since Specialization

Citations

This map shows the geographic impact of Suzanne Hendrix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Hendrix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Hendrix more than expected).

Fields of papers citing papers by Suzanne Hendrix

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Hendrix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Hendrix. The network helps show where Suzanne Hendrix may publish in the future.

Co-authors

The 25 scholars most cited alongside Suzanne Hendrix, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Suzanne Hendrix Line = papers co-authored together Suzanne Hendrix links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 132 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial The Lancet Neurology ·Gordon Wilcock, Sandra E. Black, Suzanne Hendrix, Kenton H. Zavitz, Edward A. Swabb, Mark Laughlin	2008	204
2	Sensory, Mechanical, and Microscopic Evaluation of Staling in Low‐Protein and Gluten‐Free Breads Cereal Chemistry ·Gene J. Ahlborn, Oscar A. Pike, Suzanne Hendrix, William M. Hess, C. S. Huber	2005	146
3	Aducanumab: Appropriate Use Recommendations Update The Journal of Prevention of Alzheimer s Disease ·Jeffrey L. Cummings, Gil D. Rabinovici, Alireza Atri, Paul Aisen, Liana G. Apostolova, Suzanne Hendrix, Marwan N. Sabbagh, Dennis J. Selkoe, Michael W. Weiner, Stephen Salloway Hit paper breakdown →	2022	126
4	ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials Journal of Neurology Neurosurgery & Psychiatry ·Jinping Wang, Veronika Logovinsky, Suzanne Hendrix, Stephanie H. Stanworth, Carlos Perdomo, Lu Xu, Shobha Dhadda, Ira Do, Martin Rabe, Johan Luthman, Jeffrey L. Cummings, Andrew Satlin	2016	115
5	An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease Alzheimer s & Dementia ·Jessica B. Langbaum, Suzanne Hendrix, Napatkamon Ayutyanont, Kewei Chen, Adam Fleisher, Raj C. Shah, Lisa L. Barnes, David A. Bennett, Pierre N. Tariot, Eric M. Reiman	2014	97
6	A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study Alzheimer s & Dementia ·Merçé Boada, Oscar L. López, Javier Olazarán, Laura Núñez, Michael A. Pfeffer, María Paricio, Jesús Lorites, Gerard Piñol‐Ripoll, José E. Gámez, Fernando Anaya, D Kiprov, José Lima, Carlota Grifols, Mireia Torres, Montserrat Costa, Jordi Bozzo, Zbigniew M. Szczepiorkowski, Suzanne Hendrix, Antonio Páez	2020	97
7	Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals Alzheimer Disease & Associated Disorders ·Douglas Galasko, N. R. Graff-Radford, Susanne May, Suzanne Hendrix, Barbara A. Cottrell, Sarah A. Sagi, Gary Mather, Mark Laughlin, Kenton H. Zavitz, Edward A. Swabb, Todd E. Golde, Michael P. Murphy, Edward H. Koo	2007	94
8	36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease Alzheimer s & Dementia ·Hilkka Soininen, Alina Solomon, Pieter Jelle Visser, Suzanne Hendrix, Kaj Blennow, Miia Kivipelto, Tobias Hartmann	2020	79
9	The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease Alzheimer s & Dementia Translational Research & Clinical Interventions ·Cristina López López, Pierre N. Tariot, Angelika Caputo, Jessica B. Langbaum, Fonda Liu, Marie‐Emmanuelle Riviere, Carolyn Langlois, Marie‐Laure Rouzade‐Dominguez, Martin Zalesak, Suzanne Hendrix, Ronald G. Thomas, Vissia Viglietta, Rob Lenz, J. Michael Ryan, Ana Graf, Eric M. Reiman	2019	79
10	The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach Alzheimer s & Dementia ·Richard Isaacson, Christine A. Ganzer, Hollie Hristov, Katherine Hackett, Emily Caesar, Randy Cohen, Robert Kachko, Josefina Meléndez‐Cabrero, Aneela Rahman, Olivia Scheyer, Mu Ji Hwang, Cara Berkowitz, Suzanne Hendrix, Monica Mureb, Matthew W. Schelke, Lisa Mosconi, Alon Seifan, Robert Krikorian	2018	76
11	FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry” Alzheimer s & Dementia Translational Research & Clinical Interventions ·Marwan N. Sabbagh, Suzanne Hendrix, John Harrison	2018	68
12	The Alzheimer’s Prevention Initiative Composite Cognitive Test Score The Journal of Clinical Psychiatry ·Napatkamon Ayutyanont, Jessica B. Langbaum, Suzanne Hendrix, Kewei Chen, Adam Fleisher, Michel Friesenhahn, Michael E. Ward, Camilo Aguirre, Natalia Acosta‐Baena, Lucía Madrigal, Claudia Muñoz, Victoria Tirado, Sonia Moreno, Pierre N. Tariot, Francisco Lopera, Eric M. Reiman	2014	63
13	Prevention trials in Alzheimer's disease: An EU-US task force report Progress in Neurobiology ·Bruno Vellas, Paul Aisen, Cristina Sampaio, María C. Carrillo, Philip Scheltens, Bruno Scherrer, Giovanni B. Frisoni, Michael W. Weiner, Lon S. Schneider, Serge Gauthier, Christine C. Gispen-de Wied, Suzanne Hendrix, Howard Feldman, Jesse M. Cedarbaum, Ronald C. Petersen, Eric Siemers, Sandrine Andrieu, David Prvulovic, Jacques Touchon, Harald Hampel	2011	52
14	CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT” The Journal of Prevention of Alzheimer s Disease ·Susan Abushakra, Anton P. Porsteinsson, B. Vellas, Jeffrey L. Cummings, Serge Gauthier, John A. Hey, Ann Power, Suzanne Hendrix, P. Wang, Li‐Jiuan Shen, John S. Sampalis, Martin Tolar	2016	50
15	Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis Alzheimer s Research & Therapy ·Alireza Atri, Suzanne Hendrix, Vojislav Pejović, Robert K. Hofbauer, John Edwards, José Luís Molinuevo, Stephen M. Graham	2015	49
16	Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs. PubMed ·Holly Posner, Rosie E. Curiel, Chris J. Edgar, Suzanne Hendrix, Enchi Liu, David Loewenstein, G. Morrison, Leslie A. Shinobu, Keith Wesnes, Philip D. Harvey	2017	43
17	Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report The Journal of Prevention of Alzheimer s Disease ·Randall J. Bateman, Kaj Blennow, Rachelle S. Doody, Suzanne Hendrix, Simon Lovestone, Stephen Salloway, Rachel Schindler, Michael W. Weiner, Henrik Zetterberg, Paul Aisen, Bruno Vellas	2019	42
18	Donanemab: Appropriate use recommendations The Journal of Prevention of Alzheimer s Disease ·G D Rabinovici, D. J. Selkoe, Suzanne E. Schindler, Paul Aisen, Liana G. Apostolova, Alireza Atri, Steven M. Greenberg, Suzanne Hendrix, R.C. Petersen, Myron Weiner, Steve Salloway, Jeffrey L. Cummings Hit paper breakdown →	2025	39
19	Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes Muscle & Nerve ·Sabrina Paganoni, Claire Watkins, Matthew Cawson, Suzanne Hendrix, Samuel P. Dickson, Newman Knowlton, Jamie Timmons, Machelle Manuel, Merit Cudkowicz	2022	35
20	Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease Alzheimer s & Dementia ·Roos J. Jutten, Kathryn V. Papp, Suzanne Hendrix, Noel Ellison, Jessica B. Langbaum, Michael Donohue, Jason Hassenstab, Paul Maruff, Dorene M. Rentz, John Harrison, Jeffrey L. Cummings, Philip Scheltens, Sietske A.M. Sikkes	2022	33

About Suzanne Hendrix

Suzanne Hendrix is a scholar working on Psychiatry and Mental health, Geriatrics and Gerontology, Pharmacology, Physiology and Statistics and Probability, having authored 132 papers that have together received 2.2k indexed citations. Recurring topics across this work include Dementia and Cognitive Impairment Research (41 papers), Alzheimer's disease research and treatments (26 papers), Cholinesterase and Neurodegenerative Diseases (26 papers), Health Systems, Economic Evaluations, Quality of Life (22 papers), Computational Drug Discovery Methods (9 papers), Parkinson's Disease Mechanisms and Treatments (8 papers), Frailty in Older Adults (8 papers) and Statistical Methods in Clinical Trials (7 papers). The work is most often cited by research in Psychiatry and Mental health (846 citations), Biological Psychiatry (116 citations), Physiology (1.1k citations), Neurology (318 citations) and Pharmacology (526 citations). Suzanne Hendrix has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Kenton H. Zavitz, Edward A. Swabb, Mark Laughlin, Gordon Wilcock, Sandra E. Black, Jeffrey L. Cummings, Gene J. Ahlborn, Oscar A. Pike, C. S. Huber and Jessica B. Langbaum. Their work appears in journals such as Alzheimer s & Dementia, The Journal of Prevention of Alzheimer s Disease, Neurology, Alzheimer s Research & Therapy and Alzheimer s & Dementia Translational Research & Clinical Interventions.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact